Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 16, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-08-12
DOI
10.1186/s13045-023-01487-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
- (2023) Seyedehdelaram Ghalehbandi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
- (2022) Ming Yi et al. Molecular Cancer
- Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
- (2022) Yan Tie et al. Journal of Hematology & Oncology
- The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
- (2022) Melissa T. Bu et al. PHARMACOLOGY & THERAPEUTICS
- Turning cold tumors hot: from molecular mechanisms to clinical applications
- (2022) Jiahui Zhang et al. TRENDS IN IMMUNOLOGY
- Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
- (2022) Mengke Niu et al. Frontiers in Immunology
- Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
- (2022) Xingcheng Yang et al. Experimental Hematology & Oncology
- Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
- (2022) Xue-Feng Liu et al. Experimental Hematology & Oncology
- Heterogeneity of the tumor immune microenvironment and its clinical relevance
- (2022) Qingzhu Jia et al. Experimental Hematology & Oncology
- Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
- (2022) Sonia A. Patel et al. CLINICAL CANCER RESEARCH
- Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
- (2022) Liangliang Xu et al. Journal of Hematology & Oncology
- Current insight into the regulation of PD-L1 in cancer
- (2022) Zhuandi Liu et al. Experimental Hematology & Oncology
- Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
- (2022) Ming Yi et al. Journal of Hematology & Oncology
- TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
- (2022) Ming Yi et al. Frontiers in Immunology
- Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
- (2022) Ming Yi et al. Journal for ImmunoTherapy of Cancer
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer
- (2021) Yingying Cao et al. Frontiers in Cell and Developmental Biology
- Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
- (2021) Mengke Niu et al. Experimental Hematology & Oncology
- Novel therapies emerging in oncology to target the TGF-β pathway
- (2021) Byung-Gyu Kim et al. Journal of Hematology & Oncology
- The biology of combination immunotherapy in recurrent metastatic head and neck cancer
- (2021) Xun Yuan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Advances of Targeted Therapy for Hepatocellular Carcinoma
- (2021) Mengke Niu et al. Frontiers in Oncology
- The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance
- (2021) Bikash Chandra Jena et al. CANCER LETTERS
- Recent advances and challenges of bispecific antibodies in solid tumors
- (2021) Yuze Wu et al. Experimental Hematology & Oncology
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
- (2020) Chunyan Lan et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
- (2020) Yun Fan et al. Journal of Thoracic Oncology
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
- (2019) Jian Chen et al. TRENDS IN MOLECULAR MEDICINE
- A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
- (2019) Shengnan Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
- (2019) Xianguang Bai et al. OncoTargets and Therapy
- Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors?
- (2019) Lukas Clemens Böckelmann et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
- (2017) Masaki Terabe et al. OncoImmunology
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Molecular control of endothelial cell behaviour during blood vessel morphogenesis
- (2011) Shane P. Herbert et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
- (2009) S. A. Bustin et al. CLINICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search